Loading...
Market
What will be the average weight loss percentage in a new Zepbound trial by end of 2025?
2
Resolution / Starting Odds
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
Published results in peer-reviewed medical journals
Story
Eli Lilly's Zepbound Achieves 20.2% Weight Loss, Surpassing Wegovy in Head-to-Head Trial
Dec 4, 2024, 02:10 PM
Eli Lilly announced that its obesity drug Zepbound (tirzepatide) has shown superior results to Novo Nordisk's Wegovy (semaglutide) in the first large, head-to-head trial of the two weight-loss medications. The SURMOUNT-5 Phase 3B trial included 751 adults with obesity or overweight, without type 2 diabetes, each having at least one obesity-related condition such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Over 72 weeks, patients taking Zepbound lost an average of 20.2% of their body weight (approximately 50.3 lbs or 22.8 kg), compared to a 13.7% weight loss (approximately 33.1 lbs or 15.0 kg) for those on Wegovy. These results indicate that Zepbound provided a 47% greater relative weight loss compared to Wegovy, highlighting its potential as a more effective treatment for obesity.
View original story
Similar markets
Less than 20% • 25%
20% to 22% • 25%
22% to 25% • 25%
More than 25% • 25%
Less than 20% • 25%
20% to 22% • 25%
22% to 24% • 25%
More than 24% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-25% reduction • 25%
26-50% reduction • 25%
51-75% reduction • 25%
76-100% reduction • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
